NCT05829187View on ClinicalTrials.gov

Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Uncomplicated Plasmodium Falciparum
Interventions
DRUG

Dihydroartemisinin

dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days

DRUG

Piperaquine

piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days

DRUG

Primaquine

Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only

DRUG

Momordica Charantia Extract

Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days

Trial Locations (1)

87255

Kori Puskesmas, Tambolaka

All Listed Sponsors
collaborator

Apt. Dian Yudianto; Dr. dr Erni J. Nelwan, Sp.PD, Ph.D; Apt.Hesty Utami Ramadaniati, M.Clin, Pharm, Ph.D

UNKNOWN

lead

Syamsudin Abdillah,Ph.D, Pharm D

OTHER